$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology
April 17, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis
April 13, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, April 13, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome
April 06, 2023 08:01 ET
|
Ocean Biomedical, Inc.
On Hermansky-Pudlak Syndrome (HPS) Awareness Day, Ocean Biomedical announces a commitment to developing viable treatment options for HPS-1 and HPS-4 Providence, RI, April 06, 2023 ...
Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARP’s Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria
March 21, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc., a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. with a “Buy” Recommendation
March 16, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by Fundamental Research...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a “Buy” Recommendation
March 14, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by EF Hutton with a...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target
February 28, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Breakthrough approach targets stage in malaria lifecycle responsible for all clinical disease and death, has potentially significantly greater efficacy compared with vaccines targeting other stages ...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
February 23, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and...
Ocean Biomedical Debuts as Publicly Traded Company Focused on Accelerating the Commercialization of Innovative Assets from Research Universities and Medical Centers
February 15, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Completes business combination with Aesther Healthcare Acquisition Corp. Ocean Biomedical stock will trade on Nasdaq under ticker symbol "OCEA" Providence, RI and New York, NY, Feb. 15, 2023 ...
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce the Award of New Patents for Novel Monospecific and Bispecific Antibodies that Suppress Multiple Cancer Types
February 09, 2023 09:15 ET
|
Aesther Healthcare Acquisition Corp.
Multiple Patents granted for Methods and Composition for Mono-specific and Bi-specific antibody approaches that suppress tumors by targeting and neutralizing elevated levels of chitinase 3-like-1...